DRTS Quote, Financials, Valuation and Earnings

Compugen Ltd. has a net margin of -- compared to Alpha Tau Medical Ltd.'s net margin of 84.43%. Alpha Tau Medical Ltd.'s return on equity of -56.68% beat Compugen Ltd.'s return on equity of 57.22%.

Alpha Tau Medical Ltd. has a consensus price target of $9.00, signalling upside risk potential of 28.21%. On the other hand Compugen Ltd. has an analysts' consensus of $5.80 which suggests that it could grow by 171.03%. Given that Compugen Ltd. has higher upside potential than Alpha Tau Medical Ltd., analysts believe Compugen Ltd. is more attractive than Alpha Tau Medical Ltd..

Alpha Tau Medical Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.896, suggesting its more volatile than the S&P 500 by 189.647%.

Alpha Tau Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Tau Medical Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.

Alpha Tau Medical Ltd. quarterly revenues are --, which are smaller than Compugen Ltd. quarterly revenues of $67.3M. Alpha Tau Medical Ltd.'s net income of -$11.7M is lower than Compugen Ltd.'s net income of $56.8M. Notably, Alpha Tau Medical Ltd.'s price-to-earnings ratio is -- while Compugen Ltd.'s PE ratio is 5.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Tau Medical Ltd. is -- versus 2.75x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Nano-X Imaging Ltd. has a net margin of -- compared to Alpha Tau Medical Ltd.'s net margin of -396.98%. Alpha Tau Medical Ltd.'s return on equity of -56.68% beat Nano-X Imaging Ltd.'s return on equity of -32.75%.

Alpha Tau Medical Ltd. has a consensus price target of $9.00, signalling upside risk potential of 28.21%. On the other hand Nano-X Imaging Ltd. has an analysts' consensus of $7.40 which suggests that it could grow by 179.25%. Given that Nano-X Imaging Ltd. has higher upside potential than Alpha Tau Medical Ltd., analysts believe Nano-X Imaging Ltd. is more attractive than Alpha Tau Medical Ltd..

Alpha Tau Medical Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nano-X Imaging Ltd. has a beta of 1.383, suggesting its more volatile than the S&P 500 by 38.349%.

Alpha Tau Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano-X Imaging Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Tau Medical Ltd. pays -- of its earnings as a dividend. Nano-X Imaging Ltd. pays out -- of its earnings as a dividend.

Alpha Tau Medical Ltd. quarterly revenues are --, which are smaller than Nano-X Imaging Ltd. quarterly revenues of $3.4M. Alpha Tau Medical Ltd.'s net income of -$11.7M is higher than Nano-X Imaging Ltd.'s net income of -$13.7M. Notably, Alpha Tau Medical Ltd.'s price-to-earnings ratio is -- while Nano-X Imaging Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Tau Medical Ltd. is -- versus 13.59x for Nano-X Imaging Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Pluri, Inc. has a net margin of -- compared to Alpha Tau Medical Ltd.'s net margin of -3470.71%. Alpha Tau Medical Ltd.'s return on equity of -56.68% beat Pluri, Inc.'s return on equity of -5662.45%.

Alpha Tau Medical Ltd. has a consensus price target of $9.00, signalling upside risk potential of 28.21%. On the other hand Pluri, Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 236.14%. Given that Pluri, Inc. has higher upside potential than Alpha Tau Medical Ltd., analysts believe Pluri, Inc. is more attractive than Alpha Tau Medical Ltd..

Alpha Tau Medical Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pluri, Inc. has a beta of 0.663, suggesting its less volatile than the S&P 500 by 33.7%.

Alpha Tau Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pluri, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Tau Medical Ltd. pays -- of its earnings as a dividend. Pluri, Inc. pays out -- of its earnings as a dividend.

Alpha Tau Medical Ltd. quarterly revenues are --, which are smaller than Pluri, Inc. quarterly revenues of $198K. Alpha Tau Medical Ltd.'s net income of -$11.7M is lower than Pluri, Inc.'s net income of -$6.9M. Notably, Alpha Tau Medical Ltd.'s price-to-earnings ratio is -- while Pluri, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Tau Medical Ltd. is -- versus 21.80x for Pluri, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XTL Biopharmaceuticals Ltd. has a net margin of -- compared to Alpha Tau Medical Ltd.'s net margin of -341.36%. Alpha Tau Medical Ltd.'s return on equity of -56.68% beat XTL Biopharmaceuticals Ltd.'s return on equity of -34.34%.

Alpha Tau Medical Ltd. has a consensus price target of $9.00, signalling upside risk potential of 28.21%. On the other hand XTL Biopharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could grow by 3599.14%. Given that XTL Biopharmaceuticals Ltd. has higher upside potential than Alpha Tau Medical Ltd., analysts believe XTL Biopharmaceuticals Ltd. is more attractive than Alpha Tau Medical Ltd..

Alpha Tau Medical Ltd. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XTL Biopharmaceuticals Ltd. has a beta of 1.193, suggesting its more volatile than the S&P 500 by 19.26%.

Alpha Tau Medical Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XTL Biopharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Tau Medical Ltd. pays -- of its earnings as a dividend. XTL Biopharmaceuticals Ltd. pays out -- of its earnings as a dividend.

Alpha Tau Medical Ltd. quarterly revenues are --, which are smaller than XTL Biopharmaceuticals Ltd. quarterly revenues of $162K. Alpha Tau Medical Ltd.'s net income of -$11.7M is lower than XTL Biopharmaceuticals Ltd.'s net income of -$553K. Notably, Alpha Tau Medical Ltd.'s price-to-earnings ratio is -- while XTL Biopharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Tau Medical Ltd. is -- versus 14.43x for XTL Biopharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.